A for-cause biopsy is performed to diagnose the cause of allograft dysfunction in kidney transplantation. We occasionally encounter ambiguous biopsy results in symptomatic kidney transplant recipients. Yet, the allograft survival outcome in symptomatic recipients with nonspecific allograft biopsy findings remains unclear. The purpose of this study was to analyze the impact of nonspecific for-cause biopsy findings in symptomatic kidney transplant recipients. We retrospectively collected records from 773 kidney transplant recipients between January 2008 and October 2021. The characteristics of transplant recipients with nonspecific findings in the first for-cause biopsy were analyzed. Nonspecific allograft biopsy findings were defined as other biopsy findings excluding rejection, borderline rejection, calcineurin inhibitor toxicity, infection, glomerulonephritis, and diabetic nephropathy. The graft outcome was compared between recipients who had never undergone a for-cause biopsy and those who had a first for-cause biopsy with nonspecific findings. The graft survival in recipients with nonspecific for-cause biopsy findings was comparable to that in recipients who did not require the for-cause biopsy before and after propensity score matching. Even in symptomatic kidney transplant recipients, nonspecific allograft biopsy findings might not be a poor prognostic factor for allograft survival compared to recipients who did not require the for-cause biopsy.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10874932 | PMC |
http://dx.doi.org/10.1038/s41598-024-54596-7 | DOI Listing |
Transpl Immunol
January 2025
Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. Electronic address:
Characteristic alterations in the urinary microbiome, or urobiome, are associated with renal transplant pathology. To date, there has been no direct study of the urobiome during acute allograft rejection. The goal of this study was to determine if unique urobiome alterations are present during acute rejection in renal transplant recipients.
View Article and Find Full Text PDFTransplantation
November 2024
Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Background: The spectrum of histological findings in transplanted kidneys from HIV-positive donors to HIV-positive recipients is relatively unexplored. This study describes the type and timing of histological diagnoses observed in this unique cohort.
Methods: Adequate biopsies were analyzed at implantation and posttransplant between September 2008 and May 2022.
J Heart Lung Transplant
October 2024
Department of Medicine, University of California San Francisco, San Francisco, California.
Mucosal or endobronchial biopsies (EBB) are typically used in the diagnosis of directly visualized bronchial lesions, infection, and sarcoidosis, but their utility in the evaluation of lung transplant recipients is controversial. EBB represents an attractive alternative to transbronchial biopsy (TBB): EBB provides straightforward sampling of airway pathology with decreased complication rates due to minimal and visualizable bleeding and the elimination of pneumothorax risk. In lung transplant recipients, EBB may be obtained when TBB is too high-risk, including in the setting of acute lung allograft dysfunction (ALAD) requiring mechanical ventilation or in advanced chronic lung allograft dysfunction (CLAD).
View Article and Find Full Text PDFJ Med Invest
October 2024
Department of Radiology, Faculty of Medical Sciences, University of Fukui, Fukui 910-1193, Japan.
Post-mortem computed tomography (PMCT) is a useful tool to investigate the cause of death. To appropriately use PMCT for cause-of-death analysis, it is necessary to know natural courses after death such as hypostasis in the lungs. We aimed to investigate the natural time-course change of postmortem chest CT findings and its pathological correlation in piglets.
View Article and Find Full Text PDFJ Urol
February 2025
UroGen Pharma, Princeton, New Jersey.
Purpose: We evaluate the efficacy and safety of UGN-102 chemoablation for the primary treatment of patients with recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer.
Materials And Methods: ENVISION is an ongoing, multinational, single-arm, phase 3 study in patients with a biopsy-proven recurrence of untreated low-grade intermediate-risk nonmuscle-invasive bladder cancer. Patients received 6 weekly intravesical instillations of UGN-102 (mitomycin; outpatient setting) and were evaluated at 3 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!